Stefan Oelrich, member of the Board of Management of Bayer AG and head of its Pharmaceuticals Division. [Photo provided to chinadaily.com.cn]
Bayer is deepening its commitment to China as the country rapidly emerges as a major source of pharmaceutical innovation, according to Stefan Oelrich, member of the Board of Management of Bayer AG and head of its Pharmaceuticals Division.
Speaking in an exclusive interview with China Daily, soon after Bayer's China Innovation Day held at the company's Berlin campus, Oelrich said China has become far more than a key market for the German healthcare giant. Increasingly, it is serving as an innovation hub feeding directly into Bayer's global research and development pipeline.
"China has one of the most dynamic innovation systems in the pharmaceuticals industry," Oelrich said. "It is a place where collaboration can directly shape the future of medicine and help patients."
Bayer sees significant opportunities to expand cooperation with Chinese biotechnology companies, hospitals and academic institutions, particularly in areas such as oncology, cardiovascular and renal diseases, as well as emerging fields including cell and gene therapies.
